Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly's Lung Cancer Drug Portrazza OK'd

This article was originally published in Scrip

Executive Summary

The FDA on Nov. 24 gave Eli Lilly and Co. the go-ahead to market Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL) in combination with gemcitabine and cisplatin in the US for patients with metastatic squamous non-small-cell lung cancer (NSCLC) – the first biologic available as a first-line therapy for the very difficult-to-treat disease, which has only a five-year survival rate.

You may also be interested in...



Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?

New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.

Lilly Executes Growth Strategy As New Products Drive Sales Gains

Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

UsernamePublicRestriction

Register

SC063802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel